These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 27866461)

  • 21. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
    Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
    Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disposition and biotransformation of the antipsychotic agent olanzapine in humans.
    Kassahun K; Mattiuz E; Nyhart E; Obermeyer B; Gillespie T; Murphy A; Goodwin RM; Tupper D; Callaghan JT; Lemberger L
    Drug Metab Dispos; 1997 Jan; 25(1):81-93. PubMed ID: 9010634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy male volunteers: characterization of polar metabolites by chemical derivatization with dansyl chloride.
    Prakash C; O'Donnell J; Khojasteh-Bakht SC
    Drug Metab Dispos; 2007 Jul; 35(7):1071-80. PubMed ID: 17431029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single-Dose, Matched Case-Control Study.
    Masters JC; LaBadie RR; Salageanu J; Li J; Shaik N
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):707-717. PubMed ID: 33356019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women.
    Chandrasekaran A; McKeand WE; Sullivan P; DeMaio W; Stoltz R; Scatina J
    Drug Metab Dispos; 2009 Jun; 37(6):1219-25. PubMed ID: 19273530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers.
    Prakash C; Cui D; Baxter JG; Bright GM; Miceli J; Wilner K
    Drug Metab Dispos; 1998 May; 26(5):448-56. PubMed ID: 9571226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans.
    Taavitsainen P; Prien O; Kähkönen M; Niehues M; Korjamo T; Denner K; Nykänen P; Vuorela A; Jungmann NA; von Bühler CJ; Koskinen M; Zurth C; Gieschen H
    Drug Metab Dispos; 2021 Jun; 49(6):420-433. PubMed ID: 33785516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans.
    Karanam B; Madeira M; Bradley S; Wenning L; Desai R; Soli E; Schenk D; Jones A; Dean B; Doss G; Garrett G; Crumley T; Nirula A; Lai E
    Drug Metab Dispos; 2007 Jul; 35(7):1196-202. PubMed ID: 17431030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [
    Guo F; Liu B; Li X; Wang H; Zhu X; Su Y; He C; Zhu M; Ding J; Xu Y; Zhao X; Wang Y; Shan R; Zhu J; Xie J; Ge Q; Fan L; Ding Y; Xie Y; Zhang C; Li H; Wang H; Zhou H
    Cancer Chemother Pharmacol; 2023 Feb; 91(2):143-156. PubMed ID: 36572783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
    Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
    Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
    Prakash C; Kamel A; Gummerus J; Wilner K
    Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolism and Disposition of Siponimod, a Novel Selective S1P
    Glaenzel U; Jin Y; Nufer R; Li W; Schroer K; Adam-Stitah S; Peter van Marle S; Legangneux E; Borell H; James AD; Meissner A; Camenisch G; Gardin A
    Drug Metab Dispos; 2018 Jul; 46(7):1001-1013. PubMed ID: 29735753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers.
    O'Donnell J; Lawrence K; Vishwanathan K; Hosagrahara V; Mueller JP
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [
    Gerisch M; Schwarz T; Lang D; Rohde G; Reif S; Genvresse I; Reschke S; van der Mey D; Granvil C
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):535-544. PubMed ID: 28714036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Excretion balance and pharmacokinetics following a single oral dose of [
    Ogasawara K; Xu C; Kanamaluru V; Siebers N; Surapaneni S; Ridoux L; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):307-314. PubMed ID: 32748109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects.
    Johnson TR; Tan W; Goulet L; Smith EB; Yamazaki S; Walker GS; O'Gorman MT; Bedarida G; Zou HY; Christensen JG; Nguyen LN; Shen Z; Dalvie D; Bello A; Smith BJ
    Xenobiotica; 2015 Jan; 45(1):45-59. PubMed ID: 25034009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [
    Zhou S; Shao F; Xu Z; Wang L; Jin K; Xie L; Chen J; Liu Y; Zhang H; Ou N
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):563-573. PubMed ID: 28730290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers.
    James A; Blumenstein L; Glaenzel U; Jin Y; Demailly A; Jakab A; Hansen R; Hazell K; Mehta A; Trandafir L; Swart P
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):751-60. PubMed ID: 26254025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
    Li F; Chin C; Wangsa J; Ho J
    Drug Metab Dispos; 2012 Sep; 40(9):1723-35. PubMed ID: 22653299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and metabolism of [
    Mancel V; Mathy FX; Boulanger P; English S; Croft M; Kenney C; Knott T; Stockis A; Bani M
    Xenobiotica; 2017 Aug; 47(8):705-718. PubMed ID: 27489076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.